EPCAM and malignant colon neoplasm: In this regard, Xie et al. increased the therapeutic efficacy of DOX against SW620 colon cancer cells by modification of MSNs with a DNA EpCAM aptamer and showed considerably increased toxicity of DOX in comparison with non-targeted MSNs [25].